Z
Zhejiang Tongyuankang
TOGETHER WE SEARCH FOR THE CURE
About Zhejiang Tongyuankang
TyK Medicines, Inc., founded in 2018, is an international biotechnology company based in China, specializing in the research and development of innovative anti-cancer drugs. The company focuses on small molecule oncological immunotherapy, aiming to provide advanced treatment options for cancer patients. TyK Medicines operates in the biopharmaceutical sector, targeting healthcare providers, research institutions, and pharmaceutical companies as its primary clients. The business model revolves around developing proprietary drug candidates and licensing them to larger pharmaceutical firms for commercialization. Revenue is generated through licensing agreements, research grants, and milestone payments. The company leverages a robust technology platform for drug discovery and development, ensuring a pipeline of promising therapeutic candidates. TyK Medicines is committed to advancing the field of oncology through cutting-edge research and strategic collaborations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Aug 2024 | $74M | $74M | Undisclosed | ↗ |
| SERIES DOther financing | Dec 2023 | $28M | $275M | CICC · Huzhou Talent Innovation Fund · Huiyu Pharmaceutical · Changxing Financial Holdings | ↗ |
Growth signals
Latest recorded traffic for Zhejiang Tongyuankang is 360 monthly website visits, up 2.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhejiang Tongyuankang in the Xuhui District ecosystem
The Zhejiang Tongyuankang office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- YHYida China Holdings
JunHe- HCHaibang Capital
- ZCZheshang Venture Capital
Series B and later8 investors entered at this stage
- ZFZhejiang Silk Road Fund
- HCHouji Capital
- YFYangtze River Fund
- KCKaicheng Capital
CICC- HFHuzhou Talent Innovation Fund
Huiyu Pharmaceutical- CHChangxing Financial Holdings
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhejiang Tongyuankang on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhejiang Tongyuankang’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









